NO20062496L - Fremgangsmater for behandling av astma - Google Patents

Fremgangsmater for behandling av astma

Info

Publication number
NO20062496L
NO20062496L NO20062496A NO20062496A NO20062496L NO 20062496 L NO20062496 L NO 20062496L NO 20062496 A NO20062496 A NO 20062496A NO 20062496 A NO20062496 A NO 20062496A NO 20062496 L NO20062496 L NO 20062496L
Authority
NO
Norway
Prior art keywords
pkc
methods
protein
agents
inhibit
Prior art date
Application number
NO20062496A
Other languages
English (en)
Norwegian (no)
Inventor
Divya Chaudhary
Cara Williams
Marion Kasaian
Suzana Marusic
Robert Czerwinski
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062496L publication Critical patent/NO20062496L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062496A 2003-12-24 2006-05-31 Fremgangsmater for behandling av astma NO20062496L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53252503P 2003-12-24 2003-12-24
US58941504P 2004-07-20 2004-07-20
PCT/US2004/043281 WO2005062918A2 (en) 2003-12-24 2004-12-22 Methods of treating asthma

Publications (1)

Publication Number Publication Date
NO20062496L true NO20062496L (no) 2006-09-11

Family

ID=34743021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062496A NO20062496L (no) 2003-12-24 2006-05-31 Fremgangsmater for behandling av astma

Country Status (14)

Country Link
US (1) US20050164323A1 (ru)
EP (1) EP1702214A4 (ru)
JP (1) JP2007525210A (ru)
KR (1) KR20060127415A (ru)
AU (1) AU2004308441A1 (ru)
BR (1) BRPI0417212A (ru)
CA (1) CA2545722A1 (ru)
CR (1) CR8398A (ru)
EC (1) ECSP066672A (ru)
IL (1) IL175351A0 (ru)
MX (1) MXPA06007094A (ru)
NO (1) NO20062496L (ru)
RU (1) RU2006126704A (ru)
WO (1) WO2005062918A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
JP4668902B2 (ja) 2003-08-07 2011-04-13 ヒーラー リミテッド 創傷治癒を促進するための薬剤組成物及び方法
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
DE102005020754B3 (de) * 2005-05-02 2007-01-11 Altana Pharma Ag Zelluläres Assayverfahren zur Identifizierung von PKCtheta-Inhibitoren
NZ566083A (en) * 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
ES2393135T3 (es) 2006-12-29 2012-12-18 Abbott Laboratories Ensayo mejorado para fármacos inmunosupresores
JP5450092B2 (ja) * 2006-12-29 2014-03-26 アボット・ラボラトリーズ 全血中の分子または薬物の検出のための診断検査
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
WO2010017473A2 (en) * 2008-08-07 2010-02-11 The Salk Institute For Biological Studies Method of identifying ikk2 activators or inhibitors
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
EP2507227B1 (en) 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
CA2801781C (en) 2010-07-21 2018-02-27 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
RU2526146C2 (ru) * 2012-09-27 2014-08-20 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ профилактики и лечения бронхиальной астмы, осложняющих ее респираторных вирусных инфекций и других воспалительных заболеваний дыхательных путей
WO2014089112A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
JP6421170B2 (ja) 2013-03-14 2018-11-07 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012530A1 (en) * 1992-11-30 1994-06-09 Biosignal Kutató Fejlesztó Kft. Polyunsaturated fatty acyl-peptide composition
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU2481800A (en) * 1998-12-17 2000-07-03 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methodsof making and using them
SE9902387D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New pharmaceutically active compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
AU2460601A (en) * 1999-12-27 2001-07-09 La Jolla Institute For Allergy Methods for identifying agents capable of modulating protein kinase c theta (pkctheta) activity

Also Published As

Publication number Publication date
EP1702214A4 (en) 2007-12-19
BRPI0417212A (pt) 2007-02-06
WO2005062918A3 (en) 2005-08-25
ECSP066672A (es) 2006-10-25
RU2006126704A (ru) 2008-01-27
AU2004308441A1 (en) 2005-07-14
WO2005062918A2 (en) 2005-07-14
MXPA06007094A (es) 2006-08-23
US20050164323A1 (en) 2005-07-28
EP1702214A2 (en) 2006-09-20
KR20060127415A (ko) 2006-12-12
IL175351A0 (en) 2006-09-05
CA2545722A1 (en) 2005-07-14
JP2007525210A (ja) 2007-09-06
CR8398A (es) 2006-10-06

Similar Documents

Publication Publication Date Title
NO20062496L (no) Fremgangsmater for behandling av astma
Cortellino et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
Xue et al. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons
Fernández-Velasco et al. TNF-α downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
WO2005030121A3 (en) Compounds, compositions and methods
NO20053112L (no) Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike.
KR20140019770A (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2002031134A3 (en) Novel serine protease genes related to dppiv
Opletalova et al. Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum‐variant patients reveals 12 new disease‐causing POLH mutations
EA200801372A1 (ru) Способы получения замещенных пиримидинов
CY1107335T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
Tossidou et al. SUMOylation determines turnover and localization of nephrin at the plasma membrane
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
Hu et al. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1
NO20060144L (no) Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav
WO2005051331A3 (en) Chaperone-based therapy for niemann-pick disease
WO2006020755A3 (en) Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
WO2006014490A3 (en) Polypeptides having alpha-glucosidase activity and polynucleotides encoding same
DE602005024442D1 (de) Wiederherstellung der aktivität von 5-enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
De La Peña et al. Inhibition of nonsense-mediated decay induces nociceptive sensitization through activation of the integrated stress response
Garbati et al. Effects on Energy Metabolism of Two Guanidine Molecules,(Boc) 2‐Creatine and Metformin
SE0202464D0 (sv) Use of compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application